PRESS RELEASE
(the dial-in number and the pin codes will be available on Adocia's website Wednesday December 16th 2015)
The transcript will be available in French on Adocia's website
www.adocia.com
Adocia's team will discuss 2015 key achievements and present an overview of current plans and priorities for 2016. Gérard Soula, President and CEO, together with Olivier Soula, R&D Director and Deputy General Manager; Valérie Danaguezian, Financial Director and Rémi Soula, Director of Business Development & Intellectual Property, will conduct the call.
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia's proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. To learn more about Adocia, please visit us at www.adocia.com.
For more information please contact:
Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.comTel.: +33 4 72 610 610 | Adocia Press Relations ALIZE RP Caroline Carmagnol and Florence Portejoie caroline@alizerp.com adocia@alizerp.com Tel.: + 33 1 44 54 36 61 |
distributed by |